Backed by Bob Langer, former Harvard prof sets out to test a new way to deliver I/O drugs — during surgery

Amber Tong

Every year, millions of cancer patients undergo surgery to get their tumors removed. But while resection can stave off cancer for some time, as many …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Backed by Bob Langer, former Harvard prof sets out to test a new way to deliver I/O drugs — during surgery

Amber Tong

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

China startup injects CRISPR therapy into the brain for the first time

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Backed by Bob Langer, for­mer Har­vard prof sets out to test a new way to de­liv­er I/O drugs — dur­ing surgery

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Backed by Bob Langer, former Harvard prof sets out to test a new way to deliver I/O drugs — during surgery